Abivax
5, rue de la Baume
Paris
75008
France
Tel: 33-0-1-53-83-08-41
Website: http://www.abivax.com/en/
Email: info@abivax.com
79 articles with Abivax
-
Abivax Presents First-Half 2020 Financial Results and Operations Update
9/24/2020
Abivax today announces its 2020 half-year financial results, as of June 30, 2020, and provides an update on its pipeline progress.
-
Clinical Catch-Up: June 29-July 3
7/6/2020
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look. -
Clinical Catch-Up: June 22-26
6/29/2020
It was a busy week for clinical trial updates. Here’s a look. -
BioSpace Global Roundup, June 18
6/18/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations. -
ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
6/15/2020
Abivax SA (Euronext Paris:FR0012333284 - ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that it has received € 5m in non-dilutive financing from Société Générale in the form of a loan guaranteed by the French state (PGE - Prêts Garantis par l'Etat).
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
BioSpace Global Roundup, March 19
3/19/2020
Companies from across the globe provide updates on their business operations and pipeline development. -
Abivax 2019 Financial Results and Operations Update
3/16/2020
Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced its 2019 yearly financial results, as of December 31, 2019, and provided an update on progress in its product pipeline.
-
Clinical Catch-Up: February 24-28
3/2/2020
The month of February ended with a flurry of clinical trial announcements. Here’s a look. -
BioSpace Global Roundup, Feb. 27
2/27/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations. -
Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma
2/26/2020
Abivax SA announced dosing of the first patient in a U.S. Phase 1/2 clinical trial of ABX196 to treat patients with hepatocellular carcinoma, the most common form of liver cancer..
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Abivax to Host Satellite Symposium at 15th Congress of the European Crohn’s and Colitis Organization (ECCO) in Vienna
1/28/2020
Satellite Symposium will focus on the continued need for innovative drugs in ulcerative colitis, the novel mechanism of action of ABX464 as well as clinical data from the Phase 2a induction and maintenance studies
-
BioSpace Global Roundup, Jan. 23
1/23/2020
Companies from across the globe provide updates on their businesses and pipelines. -
Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis
1/22/2020
Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for their lead drug candidate ABX464, allowing the initiation of clinical trials in the U.S. in patients with moderate-to-severe ulcerative colitis (UC).
-
BioSpace Global Roundup, Nov. 28
11/28/2019
Companies from across the globe provide updates on their businesses and pipelines. -
Clinical Catch-Up: October 21-25
10/28/2019
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look. -
BioSpace Global Roundup, Aug. 22
8/22/2019
Companies from across the globe provide updates on their business and pipelines.